Eiger BioPharmaceuticals, Inc. (EIGR) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Palo Alto, CA, アメリカ. 現CEOは David Apelian.
EIGR を有する IPO日 2014-01-30, 56 名の正社員, に上場 NASDAQ Global Market, 時価総額 $2.55M.
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.
